Primary mediastinal (thymic) large B cell lymphoma
Mediastinal large B cell lymphoma | |
---|---|
Classification and external resources | |
Specialty | Hematology and oncology |
ICD-O | 9679/3 |
Primary mediastinal (thymic) large B-cell lymphoma, also called primary mediastinal large B-cell lymphoma (PMLBCL) and mediastinal large B-cell lymphoma, is a distinct type of diffuse large B-cell lymphoma involving the mediastinum, recognized in the WHO 2008 classification.[1][2]:370-374
Biology
PMLBCL arises from a putative thymic peripheral B cell.[3][4] It has several distinctive biological features.[3] Molecular analysis shows that PMLBCL is distinct from other types of diffuse large B-cell lymphomas (DLBCL).[4] MAL gene expression is seen in 70%, unlike other diffuse large B-cell lymphomas.[2]:370 Gene expression profiling shows considerable variance from other DLBCLs and similarity to Hodgkin disease.[5]:290-293
PMLBCL is CD20 positive, expresses pan-B markers including CD79a, and has clonal immunoglobulin gene rearrangements and mRNA but paradoxically does not express cytoplasmic or cell surface immunoglobulin.[2]:370
Clinically, PMLBCL is unusual in several respects. It affects primarily young adults; the median age is 37 years.[2]:370 It is more common in females.[3] Despite 80% PMLBCL being stage I or II, the presenting anterior mediastinal mass is often over 10 cm and is locally invasive of lung, chest wall, pleura, and pericardium.[3] Superior vena cava syndrome occurs in 30-50%, and pleural or pericardial effusions occur in about one-third.[3] At initial presentation, PMLBCL is usually confined to mediastinum, but its bulk, rather than additional adenpathy, can sometimes may be palpated at the low neck.[3] Increased LDH is seen in approximately 75%,[2]:370[3] but unlike other large cell lymphomas, no increase in beta-2 microglobulin is seen even when bulky[2]:370 which may relate to defective major histocompatibility complex expression.[2]:370
Treatment
Multiagent chemotherapy is recommended, but the preferred regimen is controversial, as is consolidative radiotherapy.[3][6][7][8]
Grey zone lymphoma
"In-between CHD and NHL"[3][9][10][11]
See also
References
- ↑ Swerdlow, Steven H.; International Agency for Research on Cancer; World Health Organization (2008). WHO classification of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours 2 (4th ed.). International Agency for Research on Cancer. ISBN 9789283224310.
- 1 2 3 4 5 6 7 Jaffe, ES; Harris NL, Vardiman JW, Campo E, Arber, DA. (2011). Hematopathology (1st ed.). Elsevier Saunders. ISBN 9780721600406. Cite uses deprecated parameter
|coauthors=
(help) - 1 2 3 4 5 6 7 8 9 Armitage, JO; Mauch PM; Harris NL; et al. (2010). "Chapter 21". Non-Hodgkin Lymphomas (2nd ed.). Lippincott Williams & Wilkins. ISBN 9780781791168.
- 1 2 Martelli M, Di Rocco A, Russo E, et al. (2015). "Primary mediastinal lymphoma: diagnosis and treatment options". Expert Rev Hematol 8 (2): 173–86. doi:10.1586/17474086.2015.994604. PMID 25537750.
- ↑ Sweetenham, J. Lymphomas (Emerging Cancer Therapeutics V3 I2). Demos. November 2, 2012. ISBN 9781936287789
- ↑ http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf
- ↑ Faris JE, LaCasce AS (2009). "Primary mediastinal large B-cell lymphoma". Clin Adv Hematol Oncol 7 (2): 125–33. PMID 19367254.
- ↑ Dabrowska-Iwanicka A, Walewski JA (2014). "Primary mediastinal large B-cell lymphoma". Curr Hematol Malig Rep 9 (3): 273–83. doi:10.1007/s11899-014-0219-0. PMC 4180024. PMID 24952250.
- ↑ http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf
- ↑ Hutchinson CB, Wang E (2011). "Primary mediastinal (thymic) large B-cell lymphoma: a short review with brief discussion of mediastinal gray zone lymphoma". Arch. Pathol. Lab. Med. 135 (3): 394–8. doi:10.1043/2009-0463-RSR.1. PMID 21366467.
- ↑ Grant C, Dunleavy K, Eberle FC, et al. (2011). "Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do?". Curr Hematol Malig Rep 6 (3): 157–63. doi:10.1007/s11899-011-0090-1. PMID 21590365.